BioCentury
ARTICLE | Company News

Lundbeck sales and marketing update

September 24, 2012 7:00 AM UTC

Lundbeck launched Treanda bendamustine in Canada for first-line treatment of chronic lymphocytic leukemia (CLL) and to treat relapsed indolent B cell non-Hodgkin's lymphoma (NHL) in patients refractory to rituximab. Health Canada approved the alkylating agent in August. The company could not be reached for details (see BioCentury, Sept. 3). ...